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Inotropic Infusions for
Chronic Congestive Heart Failure
Medical Miracles or Misguided Medicinals?
Gordon A. Ewy, MD, FACC
Tucson, Arizona
There are numerous advertisements (1–7) and an occasional
article (8–11) advocating intermittent infusions of milri-
none or dobutamine for both inpatient and outpatient
therapy of chronic heart failure. This development is of
concern, because chronic administration of these same
agents has been shown to increase mortality rates.
One can hardly open a cardiology journal without en-
countering advertisements urging physicians to “open new
doors” to the treatment of congestive heart failure with a
drug that “helps the heart work smarter, not harder™”
(1–7). This drug, intravenous milrinone (1–7), is said to
increase cardiac index while decreasing pulmonary capillary
wedge pressure and systemic vascular resistance, avoid
significant change in myocardial oxygen consumption or
heart rate, have a rapid hemodynamic response, an easy
dosing and administration schedule, a low incidence of side
effects and no evidence of tachyphylaxis (1–7).
Perhaps as a tribute to the effectiveness of advertising, to
the obsession of hospitals with cost containment, or to the
fascination that cardiologists have with hemodynamics,
there is also a growing interest in establishing “heart failure
clinics” that provide intermittent milrinone or dobutamine
infusions therapy of chronic heart failure (8–11). Recom-
mendations are as follows:
“. . . early, aggressive treatment with IV inotropic therapy
has emerged as a strategy for the treatment of advanced
heart failure. Recently, interest in the use of these agents in
an outpatient setting has increased because of efforts to
reduce health care costs. Short term, intermittent IV ino-
tropic therapy can be safely administered to stable outpa-
tients with advanced heart failure, with a goal of improving
functional level and avoiding hospitalization” (9).
The intermittent infusion of inotropic drugs in these heart
failure clinics is designed to decrease the frequency of
hospitalizations—a laudable goal for a condition that is
consuming a significant portion of the health care dollar.
The intravenous inotropic agents presently advocated are
milrinone and dobutamine. Both milrinone and dobut-
amine improve the hemodynamics of patients with heart
failure (1–17). Dobutamine’s inotropic effect is via its beta
agonist action. Dobutamine initiates a cascade that increases
adenylate cyclase activity converting adenylate triphosphate
(ATP) to cyclic adenylate monophosphate (AMP), the
intracellular second messenger of the myocyte that results in
the release of calcium from the sacoplasmic reticulum to the
contractile proteins—thus its positive inotropic effect. In
contrast, milrinone and amrinone increases the intracellular
second messenger cyclic AMP by inhibiting phosphodies-
terase, the enzyme that breaks down cyclic AMP (18–20).
If positive inotropic effect of the milrinone and dobut-
amine improve hemodynamics of patients with chronic
heart failure, why might one question the practice of
intermittent dobutamine or milrinone infusion for chronic
heart failure? A review of the published studies of chronic
inotropic therapy in patients with chronic heart failure
reveals that all chronically administered positive inotropic
drugs that increase intracellular cyclic AMP by one mech-
anism or another have been shown to increase mortality in
patients with heart failure (Table 1).
The mortality studies of intravenous infusion of dobut-
amine are difficult to find because the two reports that
suggest a deleterious outcome are published only in abstract
form. Table 2 summarizes the control trials with intrave-
nous dobutamine therapy in advanced heart failure that
reported mortality.
In the (DICE) study, three patients in the intermittent
dobutamine group went on to cardiac transplantation and
one patient had to have dobutamine discontinued because of
severe ventricular arrhythmias (21). Thus, if mortality, need
for cardiac transplantation, and severe arrhythmias are
added, 9/19 or 47% of the dobutamine treated group had
adverse outcome compared with 3/19 or 16% of the control
group (21).
The adverse effect of long term oral inotropic therapy
with amrinone in patients with severe heart failure is also
not well known, having been published in 1984 (20). In that
study, Packer and associates reported that
“stroke volume and stroke work indexes increased markedly
during the first 48 hours of therapy, returned to pretreat-
ment values in 2 to 10 weeks, but on drug withdrawal
deteriorated rapidly to values significantly lower than those
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observed before treatment with amrinone (,.01) despite
similar values for left ventricular filling pressure, mean
arterial pressure and systemic vascular resistance” (20).
The information on the increased mortality from chronic
oral milrinone therapy in patients with chronic congestive
heart failure is easier to find, having been published in 1991
in the New England Journal of Medicine (24). The PROM-
ISE research group randomized 1,088 patients with class III
and IV heart failure to oral milrinone or placebo. The
median period of follow up was 6.1 months. As compared
with the placebo, milrinone therapy was associated with a
34% increase in cardiovascular mortality (24). In NYHA
class IV patients there was a 53% increase in mortality in the
milrinone treated group (24).
If positive inotropic agents improve hemodynamics, why
might they be harmful?
Once decreased ventricular systolic function occurs, the
patient may be asymptomatic for years, yet there is a
progressive and nearly relentless deterioration of ventricular
function mediated by as yet incompletely understood stim-
uli. Neurohormonal activation is thought to be a major
contributing factor. An elevated serum catecholamine level
is no doubt one of the stimuli, because in patients with
chronic heart failure, the higher the serum norepinephrine
level the worse the prognosis (29); beta-adrenergic blocking
agents not only improve ventricular function (30) but also
the prognosis of patients with chronic heart failure due to
systolic dysfunction (31,32). It would therefore be logical to
conclude that beta stimulation of the chronically failing
heart is deleterious. Beta-stimulation increases intracellular
cyclic AMP. Other inotropic drugs that increase intracellu-
lar cyclic AMP (Table 1) increase mortality and therefore
probably contribute to the progressive myocardial deterio-
ration seen in patients with decreased ventricular function.
Katz hypothesized that the decrease in contractile state in
heart failure is an important compensatory mechanism that
decreases energy use by the failing heart and thereby
improves the long-term survival of the cardiac muscle cell
(18,20). To quote from Packer and associates,
“Consequently, augmentation of the inotropic state by a
variety of drugs . . . could produce a temporary improve-
ment in cardiac contractile performance at the expense of
increasing myocardial energy consumption and accelerating
death of the myocardial cell. Such a sequence of events may
be particularly likely to occur with drugs that enhance
inotropy by increasing intracellular levels of cyclic AMP;
this nucleotide exerts a direct toxic effect on myocardial
cells, which is heightened by agents that stimulate its
synthesis (such as catecholamines) or retard its degradation
(such as phosphodiesterase inhibitors)” (20).
If a patient with poor ventricular function has a dramatic
improvement in hemodynamics with intermittent dobut-
amine infusion, one should suspect hibernating or stunned
myocardium and consider coronary revascularization to
improve myocardial perfusion. Infusing dobutamine into a
patient who has diffuse coronary disease and heart failure
(due in part to hibernating myocardium that is not amena-
ble to revascularization) temporarily increases myocardial
contractility, overriding the autoprotective effect of hiber-
nation.
Is intermittent intravenous therapy with the same drug
that has been shown to increase mortality when given
chronically in an oral form good medicine? Is intermittent
therapy with such a drug safe when chronic oral therapy is
not? One would think that the burden of proof should be on
those advocating intermittent intravenous therapy. This
question needs to be addressed by appropriately designed
studies.
It is difficult to rationalize the use of a drug intravenously
and intermittently when its chronic oral use has clearly been
shown to be deleterious. There should be a moratorium on
the routine use of intermittent infusion of both milrinone
and dobutamine for chronic heart failure until well designed
randomized double-blind studies are performed. In such
studies, the patients should be fully informed that although
inotropic therapy might make them feel better, it also might
shorten their life expectancy.
Table 1. Inotropic Agents that Increase Mortality in Patients
with Chronic Heart Failure
Amrinone (20)
Dobutamine (Table 2)
Enoximone (22)
Ibopamine (23)
Milrinone (24–26)
Vesnarinone (27)
Xamoterol (28)
Table 2. Randomized Mortality Trials of Intravenous
Dobutamine Therapy in Patients With Severe Heart Failure
Author (*)
Dobutamine
Mortality
Control
Mortality
Leier et al (13) 2/15 1/11
Dies et al (33) 13/31 5/29
DICE study (21) 5/19 3/19
Total 20/65 9/59
Percent 31% 15%
*Reference.
Abbreviations and Acronyms
ACE 5 angiotensin converting enzyme
AMP 5 adenylate monophosphate
ATP 5 adenylate triphosphate
NYHA 5 New York Heart Association
PROMISE 5 Prospective Randomized Milrinone
Survival Evaluation
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Should prolongation of life be the only goal of therapy? It
is argued that a significant number of patients would rather
live more comfortably even if their lives are shorter. This is
a philosophical issue that to be answered, one has to know
how much shorter; days, weeks, months, years? This has not
been studied, but chronic oral administration milrinone
shortens patients lives considerably (24).
Another question that is asked concerns the small sub-
group of class IV hospital-bound patients who require
continuous intravenous inotropes for stability. Should they
be considered for home intravenous therapy even if it
shortens their life? Using intravenous inotropes in this
situation is analogous to placing a balloon pump in a patient
with hypotension who does not have a reversible cause.
Then the question is “When do you turn it off or take it
out?” It should not have been used in the first place.
In my long experience treating patients with severe heart
failure due to systolic dysfunction, using the combination of
appropriate doses of digoxin, diuretics, ACE-inhibitors,
and, at times, a third generation beta-blocker, I have not
had to use intravenous inotropic therapy, except for the
indications outlined in the paragraph below.
Intravenous inotropic therapy should only be recom-
mended as temporary support for stunned or hibernating
myocardium that has been revascularized, or in appropriate
hemodynamically unstable patients where there is a specific
goal of temporary hemodynamic support until effective
therapy can be initiated. Examples include temporary sup-
port for an acutely ill patient until one determines if there is
a treatable or reversible cause, a patient with possible
hibernating myocardium until the patient could be studied
and revascularized, a patient with stunned myocardium who
has been revascularized or as a bridge to cardiac transplan-
tation.
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